• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is Mineralys Therapeutics (MLYS) A Bargain On Phase 3 Lorundrostat Data?

    Simply Wall St·10/25/2026 17:29:49
    語音播報

    Mineralys Therapeutics (MLYS) drew fresh attention after presenting Phase 3 lorundrostat data at ASN Kidney Week 2026, highlighting blood pressure and albuminuria reductions in patients with chronic kidney disease and uncontrolled hypertension.

    Despite the strong Phase 3 readout, Mineralys Therapeutics’ recent trading tells a different story. The share price is US$20.55 after a 1-day share price return that fell 4.29%, capping a 30-day share price return down 20.53% and a year-to-date share price return down 42.45%. At the same time, the 3-year total shareholder return is still very large at around 17x, which points to earlier enthusiasm now giving way to fading momentum as investors reassess both lorundrostat’s potential and the risks around execution.

    Spot 21 high quality undiscovered gems that, like Mineralys Therapeutics after its lorundrostat data, could be quietly repricing clinical risk long before it shows up in headline returns.

    Bulls see lorundrostat’s Phase 3 win and a large discount to analyst targets. Bears point to losses, execution risk and a sliding chart. Which side does the current valuation of Mineralys Therapeutics lean toward?

    Most Popular Narrative: 58% Undervalued

    With Mineralys Therapeutics last closing at $20.55 against a widely followed fair value of $48.50, the valuation gap the narrative highlights leans heavily on lorundrostat turning today’s clinical story into tomorrow’s revenue engine under a 7.43% discount rate.

    Progress toward an NDA filing for lorundrostat in uncontrolled and resistant hypertension, supported by multiple Phase III and proof of concept trials, positions the company to potentially transition from a pure R&D story toward a revenue generating profile, which could materially affect future revenue and earnings visibility.

    See why 4 investors see Mineralys Therapeutics as 58% undervalued.

    Result: Fair Value of $48.50 (UNDERVALUED)

    Still, the lorundrostat story hinges on regulatory approval and eventual uptake, and delays, extra data requests, or slower prescribing could quickly challenge that undervalued thesis.

    Find out about the key risks to this Mineralys Therapeutics narrative.

    Next Steps

    Mixed feelings on Mineralys Therapeutics so far. If the push and pull between risks and rewards feels sharp, move quickly, review the full spread of evidence yourself, and then weigh the 2 key rewards and 1 important warning sign.

    Looking for more investment ideas beyond Mineralys Therapeutics?

    If Mineralys Therapeutics has you rethinking how you spot opportunity and risk, do not stop here. Put that curiosity to work across a broader watchlist.